InsiderTrades

Form 4 for MAZE Maze Therapeutics, Inc.

Accepted 2026-02-02 00:00:00 ET · period of report 2026-01-29 · accession 0002050167-26-000003 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-02-02 2026-01-29 MAZE Dandekar Atul CSBO S - Sale+OE $44.26 -7,500 13.3K -36% -$332.0K
D 2026-02-02 2026-01-29 MAZE Dandekar Atul CSBO M - OptEx $10.42 +7,500 18.0K +71% +$78.2K
D 2026-02-02 2026-01-29 MAZE Dandekar Atul CSBO M - OptEx $0.00 -7,500 66.6K -10% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-01-29 S D 1,200 $43.18 16,803 D — — (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
2 Common Common Stock 2026-01-29 S D 2,800 $45.01 10,503 D — — (F4) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.53 per share, inclusive.
3 Common Common Stock 2026-01-29 S D 3,500 $44.04 13,303 D — — (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.51 to $44.49 per share, inclusive.
4 Common Common Stock 2026-01-29 M A 7,500 $10.42 18,003 D — —
5 Derivative Stock Option (Right to Buy) 2026-01-29 M D 7,500 $0.00 66,643 D $10.42 · — to 2031-04-11 7,500 Common Stock (F5) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.